Home Compliance Novartis’ and Alcon’s $345 Million FCPA Case Signals Increased Scrutiny of Gifts... ComplianceExpert OpinionFCPANews Novartis’ and Alcon’s $345 Million FCPA Case Signals Increased Scrutiny of Gifts and Entertainment and Renewed Focus on Scientific Studies July 24, 2020 39 Share FacebookLinkedinTwitter Taljat David | Shutterstock You must be a Paid or Free Trial Member to Access this Content. Paid members, please login to view your news subscription(s). RELATED ARTICLESMORE FROM AUTHOR Compliance When Advocacy Turns Into Obstruction: A Cautionary Tale for Corporate Counsel Handling Gov’t Investigations Compliance March 2024 Developments Under President Biden’s Cybersecurity Executive Order, National Cybersecurity Strategy, and AI Executive Order Cyber Better Safe Than Sorry: OMB Releases Memorandum on Managing AI Risks in the Federal Government